@article {2291, title = {Renal Resistive Index and Estimated Glomerular Filtration Rate in Nondiabetic Chronic Kidney Disease Stage 3: A Cross-Sectional Analytical Study}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {June 2024}, pages = {538-544}, type = {Original Article}, chapter = {538}, abstract = {

Background: Renal resistive index (RRI) and estimated glomerular filtration rate (eGFR) are predictive markers for chronic kidney disease (CKD) progression. Aim: To evaluate RRI value, eGFRcr-cys and renal biomarker in nondiabetic patients with CKD stage 3 in Bangkok, Thailand. Methods: A cross-sectional analytical analysis was conducted involving nondiabetic patients with CKD stage 3, aged 35-85 years. Ultrasound was used to assess the RRI of arteries in both kidneys. Patients underwent assessments of serum and urine 24-hour. Results: Among the 61 participants (67.2\% male; mean age 69.03 {\textpm} 12.59 years), the mean eGFRcr-cys was 41.63 {\textpm} 8.64 mL/min/1.73 m{\texttwosuperior}, and the mean RRI was 0.65 {\textpm} 0.06. Patients were categorized into three RRI groups: low (\<0.65, n=35), intermediate (0.65-0.70, n=14), and high (\>0.70, n=12). The high RRI group showed a mean RRI of 0.73 {\textpm} 0.05 (p \< 0.01). Among those with high RRI group were significant decreased right kidney size (p\<0.05) and they had a lower BMI, averaging 22.49 {\textpm} 3.48. An increase in PP (59.66 {\textpm} 13.84, p=0.04) was also significant in this group. The correlations coefficient of RRI value showed a significant positive correlation with age (p\<0.05) and significant negative with BMI (p\<0.05). In addition, eGFRcr-cys displayed a significant negative correlation with UAGT and 24hUP (p\<0.05) and a significant while eGFRcr-cys positive correlation with both kidney size and urine iNOS(p\<0.01). Conclusion: An increase in RRI is inversely linked to age, BMI, and PP. Lower eGFR is correlated with factors that cause CKD progression.

}, doi = {10.5530/pj.2024.16.85}, author = {Patnaree Wongmanit and Kusuma Sriyakul and Parunkul Tungsukruthai and Ouppatham Supasyndh and Pratya Phetkate} } @article {2149, title = {Safety Assessment of Supplementation with Cymbopogon citratus Stapf. (Lemongrass) Extract in Patients with Chronic Kidney Disease Stage 3: A Preliminary 90-Days Prospective Study}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {December 2023}, pages = {976-986}, type = {Original Article}, chapter = {976}, abstract = {

Background: Chronic kidney disease is a major public health issue, and due to resource constraints, many can{\textquoteright}t access dialysis. C. citratus, lemongrass is globally prevalent and known to increase urine output without toxicity. Objective: To examine the safety of C. citratus in patients with CKD stage 3. Materials and Methods: The major compound of C. citratus was analyzed using high-performance liquid chromatography (HPLC). 64 patients were enrolled and randomly assigned to control or C. citratus groups. The control group received a placebo, whereas the C. citratus group received 900 mg of C. citratus daily for 90 days. All participants were examined BUN, Scr, Cys-C, and eGFR, liver functions, RBC, HCT, Na+, K+, Cl-, and HCO3, and other biochemical parameters. Results: HPLC showed C. citratus contains of phenolic compounds. Clinically, C. citratus group had no notable side effects on T-Bil, AST, ALT and ALP. Also, maintained eGFR, SCys-C, K+ and Cl level. The level of blood Na+ was significant increase at day 30 (p \< 0.05). The control group had a significant decrease in eGFR and HCO3 levels (p \< 0.05) and a significant increase of Cl- and SCys-C. In addition, no statistical differences had found between groups in eGFR, BUN, Cr, Na+, K+, HCO3, PO4, RBC and HCT levels. Throughout the 90 days, no drug allergies or side effects were reported. Conclusion: Dietary supplementation with C. citratus may have a favorable effect on delaying the course of CKD and is safe to use for patients with CKD stage 3.

}, keywords = {Chronic Kidney Disease, CKD stage 3, Cymbopogon citratus Stapf., Lemongrass, Safety}, doi = {10.5530/pj.2023.15.181}, author = {Patnaree Wongmanit and Parunkul Tungsukruthai and Pratya Phetkate and Daraporn Rungprai and Sucharat Tungsukruthai and Ouppatham Supasyndh and Kusuma Sriyakul} }